Cargando…
Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
If mathematical modeling is to be used effectively in cancer drug development, future models must take into account both the mechanistic details of cellular signal transduction networks and the pharmacokinetics (PK) of drugs used to inhibit their oncogenic activity. In this perspective, we present a...
Autores principales: | Kirouac, D C, Onsum, M D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026631/ https://www.ncbi.nlm.nih.gov/pubmed/24005988 http://dx.doi.org/10.1038/psp.2013.38 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022) -
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014) -
Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
por: Bender, Brendan C, et al.
Publicado: (2015) -
Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
por: Papachristos, Apostolos, et al.
Publicado: (2023) -
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)